Articles tagged with Schizophrenia
Researchers found that family function is affected by the mental illness diagnosis type and caregiver sense of coherence. Caregiver strain and client dependence are associated with greater family disruption. Interventions for all family members may improve cohesion and support.
Scientists have identified a neural circuit in the mouse brain that regulates attention and sensory processing, providing insight into how the brain filters out distractions. The discovery has implications for devastating psychiatric disorders such as schizophrenia, which are characterized by significant attention deficits.
Scientists at CAMH have discovered a novel drug target that could lead to better antipsychotic medications for schizophrenia patients. The discovery, led by Dr. Fang Liu, identifies a protein combination that disrupts symptoms without side-effects.
New Rutgers research suggests that an overabundance of the NOS1AP protein in developing brains can lead to abnormalities and faulty connections, potentially triggering schizophrenia. The study's findings offer a potential explanation for the biological process of the disease and may pave the way for targeted treatment therapies.
The Brain & Behavior Research Foundation has awarded NARSAD Distinguished Investigator Grants to 15 scientists conducting innovative projects in neurobiological and behavioral research. The grants are valued at $1.5 million and aim to understand and treat psychiatric disorders affecting one in four people.
Researchers developed a family-focused, culturally-informed treatment for schizophrenia that reduced patients' psychiatric symptoms and improved caregiver emotional well-being. The program tapped into the family's cultural beliefs, values, traditions, and religious practices to help them manage the illness.
Researchers develop robot that induces feeling of 'ghost' presence in healthy participants by sending mixed-up sensorimotor signals. The phenomenon is linked to damage in frontoparietal cortex and may shed light on schizophrenic hallucinations.
A new study suggests that approximately one-fifth of schizophrenia cases may be attributable to T. gondii infection, according to professor Gary Smith's epidemiological modeling. This finding implies that preventing infections with this parasite could prevent about one-fifth of all schizophrenia cases over a lifetime.
Researchers developed an EEG test to help diagnose persons at risk of developing mental illness and measure the effectiveness of treatment options. The test measures auditory processing deficits in schizophrenia patients, suggesting potential improvement with cognitive exercises.
A comprehensive meta-analysis of robust studies shows that anti-inflammatory medicines, such as aspirin, can add to the effective treatment of schizophrenia. The study suggests that selecting specific anti-inflammatory agents could lead to improved patient responses and new treatment approaches.
Patients with first episode psychosis face elevated risks of heart disease and metabolic issues due to mental illness, unhealthy lifestyle behaviors, and antipsychotic medications. A team-based healthcare approach is necessary to address these needs and improve overall health.
The study found that patients with schizophrenia who took antipsychotic medication had higher triglycerides, insulin, and insulin resistance. Obesity was also linked to longer duration of psychiatric illness and increased risk of cardiovascular disease. Higher body mass index and waist circumference were associated with worse outcomes.
Two UC San Diego professors, David Braff and Gregory Light, have been recognized for their contributions to schizophrenia research. They developed innovative methods to identify biomarkers and create new psychosocial and pharmaceutical therapies for the disorder.
A new study from Brown University pinpoints working memory as a source of learning difficulties in people with schizophrenia. Researchers found that only working memory was impaired in individuals with the condition, highlighting its unique role in making learning more challenging.
The Brain & Behavior Research Foundation recognized eight scientists with Outstanding Achievement Prizes for their work on psychiatric disorders, affecting one in four people. Recipients include Drs. David Braff and Patrick Sullivan, who pioneered schizophrenia and mood disorder research.
Researchers will sequence the genomes of 10,000 people with European, Hispanic, and African-American ancestry to better understand two mental health disorders. The goal is to identify genetic targets for drug development and improve disease prediction.
Dr. Patrick F. Sullivan, a psychiatric geneticist, received the 2014 Lieber Prize for his distinguished work on schizophrenia. He heads large international projects and directs mega-analyses involving 90,000 participants.
A multi-institutional team will sequence total genomic DNA from 10,000 or more ethnically diverse individuals to identify genetic variants associated with schizophrenia and bipolar disorder. The Genomic Psychiatry Cohort at Keck School of Medicine of USC comprises over 37,000 participants.
Researchers at University of North Carolina Health Care developed a blood test that identifies individuals at high risk for developing psychosis. The test measures immune and hormonal system imbalances, as well as oxidative stress, and shows promise in predicting the development of severe mental disorders like schizophrenia.
A new study found that schizophrenia patients have lower levels of nicotine receptors in the brain and experience improved social withdrawal and cognitive function after smoking. Smoking-related increases in nicotine receptors were also associated with better outcomes in these patients.
Researchers studied brain development in people with and without schizophrenia, finding altered trajectories of growth in highly-connected brain regions. The findings provide clues to the underlying causes of schizophrenia, supporting a neurodevelopmental disorder hypothesis.
New research reveals schizophrenia to be a group of eight genetically distinct disorders, each with its own set of symptoms. The study analyzed genetic influences on over 4,000 people with schizophrenia and identified distinct gene clusters that contribute to the condition.
Research finds associations between psychotic disorders and reduced cortical folding patterns in key brain regions, suggesting alterations in brain development early in life. The study's results also indicate a potential familial risk marker for psychotic illnesses.
Using human induced pluripotent stem cells (hiPSCs), researchers discovered that schizophrenia patients' hiPSC-derived neurons release more neurotransmitters, including dopamine. This finding could lead to a better understanding of brain disorders and the development of new therapeutic strategies.
Researchers found that neurons from schizophrenia patients secrete higher amounts of dopamine, norepinephrine, and epinephrine. This discovery offers a new insight into the chemical basis of schizophrenia, potentially leading to new drug targets and therapies.
A prior OCD diagnosis is associated with an increased risk of developing schizophrenia and schizophrenia spectrum disorders later in life. The children of parents diagnosed with OCD also show a heightened risk of developing schizophrenia and related disorders.
Research from San Francisco State University finds that individuals with schizophrenia struggle to set high-effort goals due to difficulty assessing effort required. Breaking down tasks into smaller ones with small rewards can help patients function normally and counter motivation deficits.
Research suggests that happiness is an attainable goal for some schizophrenia patients, associated with positive psychological and social attributes like resilience and optimism. A study found that 37% of patients reported being happy all or most of the time, regardless of severity, duration, or socioeconomic factors.
People with schizophrenia struggle to convert desires into actions due to brain deficits affecting the caudate region. This impairment prevents them from making choices and behaving accordingly. The study's findings suggest that schizophrenics are 'stuck in neutral', wanting a normal life but unable to take necessary steps.
A recent study using stem cells found that a rare genetic variation, known as DISC1, reduces synapse growth in young brain cells, contributing to schizophrenia and depression. The researchers also discovered that the variation regulates the activity of over 100 genes related to synapses.
A recent study has found that a rare genetic mutation in the DISC1 gene can corrupt neural connections, leading to disruptions in brain circuitry. The research, published in Nature, used induced pluripotent stem cells to model the effects of the mutation on human neurons.
Researchers have discovered a mechanism to develop drugs that can control schizophrenia symptoms without causing common anti-psychotic side effects. By targeting the dopamine D2 receptor, the 'dimmer switch' approach aims to subtly dial down dopamine's effect, potentially treating the disease and avoiding side-effects.
New study reveals a significant relationship between motivational deficit and poor cognitive performance in people with schizophrenia. Lower levels of motivation are associated with greater cognitive impairment, suggesting that understanding the impact of motivational impairment is crucial for improving treatments.
A new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism found that individuals with schizophrenia have lower levels of vitamin D than healthy people. People with vitamin D deficiency are 2.16 times more likely to have schizophrenia, highlighting a potential connection between vitamin D and psychi...
Researchers have identified over 100 locations in the human genome associated with the risk of developing schizophrenia, pointing to genetic variations that make people vulnerable to psychiatric disease. The study's findings could lead to new approaches to treating the disorder and inform drug development for acute need.
Researchers identified previously unknown areas of genetic material linked to schizophrenia and found associations with immune system genes. The study suggests potential treatments for autoimmune disorders and provides new targets for drug development.
A rare gene variant associated with a threefold risk of bipolar disorder, a two-to-three-fold increased risk of schizophrenia or alcohol dependence, and a threefold risk of developing the condition. The variant is found in approximately one in every 200 people.
A UK-led study has discovered over 100 genetic risk factors linked to schizophrenia, shedding light on the biological cause of the condition. The findings point to new biological mechanisms and pathways, including genes associated with schizophrenia being active in the immune system.
Researchers have discovered 108 genetic loci associated with schizophrenia, a significant increase from the 30 previously reported. The study suggests that these genetic variations may exert their effects by turning genes on or off rather than coding for proteins.
Researchers have identified over 100 genetic locations associated with schizophrenia risk, revealing biological pathways that could inform new treatment approaches. The study expands understanding of the disorder's genetic basis and underlying biology.
A multinational collaboration has identified over 100 locations in the human genome associated with schizophrenia risk, shedding light on biological mechanisms and pathways. The study could lead to new approaches to treating the disorder, which has seen little innovation in drug development for over 60 years.
Researchers found a link between antipsychotic medication and reduced brain volume in schizophrenia patients, but no impact on cognitive function or symptoms over a nine-year follow-up. The study suggests that both older and newer antipsychotics may be associated with similar declines in brain volume.
Researchers found that schizophrenia patients exhibit altered brain activity in the ventro-lateral prefrontal cortex, leading to impaired ability to control working memory. This deficit is characterized by increased activation of irrelevant information, hindering cognitive function.
Researchers found that higher levels of C-reactive protein in maternal blood were significantly associated with an increased risk of schizophrenia in offspring. The study suggests that pregnancy-related inflammation may play a role in the development of schizophrenia, providing new insights into its biological mechanisms.
A Johns Hopkins study finds that a gene deletion linked to schizophrenia alters brain cell skeletons, disrupting layer formation. Researchers also identify a crucial protein involved in building cellular skeletons, which may contribute to the condition.
Researchers describe a new strategy that pinpoints a genetic variant predisposing individuals to schizophrenia and reveals deficits in nerve development. The study uses induced pluripotent stem cells to identify CYFIP1 as a critical gene maintaining nerve cell structure.
Researchers at University of Maryland School of Medicine will examine the role of kynurenic acid in schizophrenia, a devastating psychiatric disease affecting one percent of people worldwide. The study aims to uncover its potential linchpin role and develop new treatment interventions.
A study by King's College London suggests that genes increasing schizophrenia risk also contribute to higher cannabis use. Individuals genetically predisposed to schizophrenia are more likely to use and consume cannabis in greater quantities.
Researchers at St. Jude Children's Research Hospital identified a disrupted brain circuit that may contribute to auditory hallucinations in schizophrenia. The study, published in Science, suggests that reducing information flow between two brain structures involved in processing auditory information sets the stage for stress triggers.
A new study reveals that exposure to air pollution early in life can produce harmful changes in the brains of mice, including enlargement of the lateral ventricles seen in humans with autism and schizophrenia. The findings are consistent with recent studies showing a link between air pollution and autism in children.
A Wayne State University study reveals that children genetically at risk for schizophrenia and bipolar disorder experience communication breakdowns in brain networks supporting attention. This dysfunction may amplify risk for psychiatric illnesses, highlighting potential premeditative intervention strategies.
Rates of adverse outcomes, including premature death and violent crime, in people with schizophrenia are increasing compared to the general population. Men and women with schizophrenia were eight times more likely to die prematurely than the general population.
A study sequencing the exome of 231 schizophrenia patients and their unaffected parents found that collective damage across several genes contributes to the disease. This discovery could lead to early detection and treatment strategies.
A study found no significant difference in effectiveness between long-acting injectable versions of second-generation and older antipsychotic medications. Participants taking paliperidone palmitate gained weight, while those taking haloperidol decanoate lost weight.
Researchers at the Salk Institute used stem cells to study neural function in people with schizophrenia, finding unusual activity in early developmental stages that may lead to diagnostic tests. The study suggests that events during pregnancy could contribute to the disease.
A decade-long study found that older adults with schizophrenia are twice as likely to receive a dementia diagnosis compared to those without the condition. However, they also experience higher rates of other serious illnesses and mortality rates, with a notable exception being lower cancer rates.
Dr. Peter F. Buckley, a psychiatrist and Dean of the Medical College of Georgia, has been awarded the Kempf Fund Award for Research Development in Psychobiological Psychiatry from the American Psychiatric Association. The award recognizes his contributions to understanding schizophrenia and improving treatments.
A study published in Molecular Psychiatry found that malfunctions in five genes - AUTS2, CDH8, MECP2, HUWE1, and TRAPPC9 - contribute to pathology in schizophrenia, autism, and intellectual disability. These genes play a crucial role in epigenetic regulation of transcription and may be essential for normal brain development.
Researchers analyzed proteins in rat brains after giving them hallucinogenic drugs, finding 352 proteins that respond to the drug and cause changes in behavior. These protein changes may be comparable to those in a schizophrenic brain, paving the way for new treatments.
A study by University of Chicago scientists found that genetic variants associated with enjoying the effects of amphetamine also reduce the risk for developing schizophrenia and ADHD. This suggests a complex role for dopamine in these diseases.